Esperion Therapeutics (United States)
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Esperion Therapeutics (United States), United States, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
51%
Total
Publications
176
Total Open
Publications
90
Total
Citations
11K
Open Access
Percentage
51%
Total
Publications
176
Total Open
Publications
90
Total
Citations
11K
Breakdown
Publisher Open
23%
Both
24%
Other Platform Open
4%
Closed
49%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 19%
16
Hybrid 65%
53
No Guarantees 16%
13
Other Platform Open
Domain 78%
39
Other Internet 22%
11
Institution 10%
5
Preprint 10%
5
Public 2%
1
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 39 |
Europe PMC | Domain | 16 |
DOI | Other Internet | 4 |
medRxiv | Preprint | 3 |
Imperial College London - Spiral | Institution | 3 |
Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca | Institution | 2 |
Le Centre pour la Communication Scientifique Directe - HAL - TYPE ART | Other Internet | 2 |
HAL | Other Internet | 2 |
bioRxiv | Preprint | 2 |
UWA - UWA Profiles and Research Repository | Other Internet | 1 |